ALS Network Partners with Target ALS to Accelerate Global ALS Research Efforts
August 21, 2025 Aiden Hipwell
The ALS Network, formerly ALS Golden West, has partnered with Target ALS to advance research through its global research program, breaking down barriers that have long slowed progress and accelerating the search for effective treatments for people living with the disease.
“The Target ALS and ALS Network missions complement one another,” Sheri Strahl, MPH, MBA, president and CEO of the ALS Network said. “This alignment allows for meaningful collaboration to advance ALS drug discovery and development programs.”
Target ALS is exploring bold new directions in ALS research through a dynamic portfolio of funded projects. Priorities center on accelerating the discovery of biomarkers that can transform how ALS is diagnosed and treated and on cultivating the next generation of ALS leaders by investing in early-career scientists and clinicians. Through collaborative research consortia and targeted grant programs, the organization is fueling breakthroughs while expanding and diversifying the global community of ALS researchers. The ALS Network is joining Target ALS in these efforts, supporting pioneering projects at leading institutions around the world, including:
- Translating novel ALS and FTD fluid biomarkers of TDP-43 pathology towards the clinic
- Liquid Biopsy for Amyotrophic Lateral Sclerosis Using Epigenetic Signatures from Plasma Cell-Free DNA
- Understanding the relevance of TDP-43-induced cryptic exon expression for synaptic dysfunction in ALS
- KCNQ2 Biomarker for Precision Medicine in ALS
- Transposable element in neuron derived extracellular vesicles: patient selection and treatment response biomarker
- Theranostic potential of profiling CD8+ T-cells in peripheral tissues of people with pre-symptomatic sporadic ALS
- Identifying Upper Motor Neuron Pathology and Molecular Signatures in the ALS Motor Cortex
- Revealing neuroprotective and neurotoxic T cell responses in amyotrophic lateral sclerosis
- RNA-directed therapy for C9orf72-linked ALS using zinc finger nucleases
“Collaboration accelerates innovation and together with the ALS Network, we are proud to support these projects,” said Manish Raisinghani, M.B.B.S., Ph.D., CEO of Target ALS. “At Target ALS, we fuel the best ideas in ALS research worldwide by providing support through funding and access to critical resources to accelerate the discovery of treatments that will change the trajectory of ALS.”